Skip to main content
SpringerLink
Log in

Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: The high curability of clinical stage I nonseminomatous germ cell tumors (NSGCTs) and the availability of equally effective management options (retroperitoneal lymph node dissection [RPLND] and surveillance) allows for treatment decisions based on secondary end points, including short- and long-term toxicity and cost relative to benefit. The purpose of this study was to perform cost-benefit and risk-benefit analyses of management options in clinical stage I NSGCT using data from the literature and Indiana University.

Methods: The overall costs for 100 patients undergoing a primary RPLND were compared with the total costs of 100 patients managed by surveillance for clinical stage I disease. These two options were then analyzed in terms of survival, late relapse, acute and chronic toxicity (including fertility), and perioperative morbidity.

Results: The overall costs of these two approaches were essentially identical. The two options were similar in terms of survival, although RPLND demonstrated superiority in terms of fertility, toxicity, and late relapse.

Conclusions: The choice of nerve-sparing RPLND or surveillance in a clinical stage I NSGCT patient cannot be made on the basis of cost as a discriminator. Instead, the decision should be made based on patient desires, physician expertise, biological predictors, and short- and long-term toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Freedman LS, Parkinson CM, Jones WAG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone.Lancet 1987;2:294–8.

    PubMed  CAS  Google Scholar 

  2. Pont J, Hoeltl W, Kosak D, et al. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial.J Clin Oncol 1990;8:16–20.

    PubMed  CAS  Google Scholar 

  3. Klepp O, Olsson AM, Henrikson H, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study.J Clin Oncol 1990;8:509–18.

    PubMed  CAS  Google Scholar 

  4. Sesterhenn IA, Weiss RB, Mostofi FK, et al. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup.J Clin Oncol 1992;10:69–78.

    PubMed  CAS  Google Scholar 

  5. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.Cancer Res 1994;54:362–4.

    PubMed  CAS  Google Scholar 

  6. de Riese WT, de Riese C, Ulbright TM, et al. Flow cytometric and quantitative histological parameters as prognostic indicators for occult retroperitoneal disease in clinical stage I nonseminomatous testicular germ cell tumors (NSGCT).Int J Cancer 1994;57:628–33.

    PubMed  Google Scholar 

  7. Moul JW, Foley JP, Hitchcock CL, et al. Flow cytometry and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.J Urol 1993;150:879–83.

    PubMed  CAS  Google Scholar 

  8. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of the optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors. A Southeastern Cancer Study Group protocol.J Clin Oncol 1989;7:387–91.

    PubMed  CAS  Google Scholar 

  9. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage I non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989.Br J Urol 1993;71:326–35.

    PubMed  CAS  Google Scholar 

  10. Donohue JP, Zachary JM, Maynard SD. Distribution of nodal metastases in non-seminomatous testicular cancer.J Urol 1982;128:315–20.

    PubMed  CAS  Google Scholar 

  11. Ray B, Hadju SI, Whitmore WF Jr. Distribution of retroperitoneal lymph node metastases in testicular germinal tumors.Cancer 1974;33:340–8.

    PubMed  CAS  Google Scholar 

  12. Sternberg C. Role of primary chemotherapy in stage I and low volume stage II non-seminomatous germ cell testis tumors.Urol Clin North Am 1993;20:93–109.

    PubMed  CAS  Google Scholar 

  13. Lowe BA. Surveillance versus nerve-sparing retroperitoneal lymphadenectomy in stage I non-seminomatous germ cell tumors.Urol Clin North Am 1993;20:75–83.

    PubMed  CAS  Google Scholar 

  14. Doubilet P, Weinstein MC, McNeal BJ. Use and misuse of the term “cost-effectiveness” in medicine.N Engl J Med 1986;314:253–6.

    PubMed  CAS  Google Scholar 

  15. Skinner DG, Leadbetter WF. The surgical management of testis tumorsJ Urol 1971;106:84–93.

    PubMed  CAS  Google Scholar 

  16. McCleod DG, Weiss RB, Stablein DM, et al. Staging relationships and outcome in early stage testicular cancer: a report from the testicular cancer intergroup study.J Urol 1991;45:1178–83.

    Google Scholar 

  17. Pizzocaro G, Salvioni R, Zanoni F. Unilateral lymphadenectomy in intra-operative stage I non-seminomatous germinal testis cancer.J Urol 1985;134:485–9.

    PubMed  CAS  Google Scholar 

  18. Fung C, Kalish LA, Brodsky GL, Richie JP, Garnick MB. Stage I non-seminomatous germ cell tumor: prediction of metastatic potential by primary histopathology.J Clin Oncol 1988;6:1467–73.

    PubMed  CAS  Google Scholar 

  19. Staubitz WJ, Early MS, Magoss IV, Murphy GP. Surgical management of testis tumorJ Urol 1974;111:205–9.

    PubMed  CAS  Google Scholar 

  20. Bredael J, Vugrin D, Whitmore WF. Recurrences in surgical stage I non-seminomatous germ cell tumors of the testis.J Urol 1983;130:476–8.

    PubMed  CAS  Google Scholar 

  21. Sogani PC, Whitmore WF, Herr HW, et al. Orchiectomy alone in the treatment of clinical stage I non-seminomatous germ cell tumor of the testis.J Clin Oncol 1984;2:267–70.

    PubMed  CAS  Google Scholar 

  22. Pizzocaro G, Zanoni F, Milani A, et al. Orchiectomy alone in clinical stage I non-seminomatous testis cancer: a critical appraisal.J Clin Oncol 1986;4:35–40.

    PubMed  CAS  Google Scholar 

  23. Hoskin P, Dilly S, Easton D, Horwich A, Hendry W, Peckham MJ. Prognostic factors in stage I non-seminomatous germ cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy.J Clin Oncol 1986;4:1031–6.

    PubMed  CAS  Google Scholar 

  24. Read G, Stenning SP, Cullen MH, et al. Medical research council prospective study of surveillance for stage I testicular teratoma. Medical research council testicular tumor working party.J Clin Oncol 1992;10:1762–8.

    PubMed  CAS  Google Scholar 

  25. Thompson PI, Nixon J, Harvey VJ. Disease relapse in patients with stage I non-seminomatous germ cell tumor of the testis on active surveillance.J Clin Oncol 1988;6:1597–603.

    PubMed  CAS  Google Scholar 

  26. Raghavan D, Colls B, Levy J, et al. Surveillance for stage I non-seminomatous germ cell tumors of the testis the optimal protocol has not yet been defined.Br J Urol 1988;61:522–6.

    PubMed  CAS  Google Scholar 

  27. Dunphy C, Ayala AG, Swanson DA, Ro JY, Logothetis C. Clinical stage I non-seminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a protocol after orchiectomy alone.Cancer 1988;62:1202–6.

    PubMed  CAS  Google Scholar 

  28. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Gierksky RE. Is postchemotherapy retroperitoneal surgery necessary in patients with non-seminomatous testicular cancer and minimal residual tumor.J Clin Oncol 1992;10:569–73.

    PubMed  CAS  Google Scholar 

  29. Donohue JP, Rowland RG, Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testicular cancer.J Urol 1987;137:1176–9.

    PubMed  CAS  Google Scholar 

  30. Pizzocaro G, Salvioni R, Pasi M, et al. Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II non-seminomatous testicular cancer.Cancer 1985;56:249–55.

    PubMed  CAS  Google Scholar 

  31. Jansen RLH, Sylvester R, Sleyfer DT, et al. Long term follow up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery.Eur J Cancer 1991;27:695–8.

    PubMed  CAS  Google Scholar 

  32. Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer?J Clin Oncol 1991;9:1393–6.

    PubMed  CAS  Google Scholar 

  33. Donohue JP, Foster RS. Retroperitoneal lymphadenectomy for clinical stage I testis cancer. Modifications of technique and impact on ejaculation.Problems Urol 1994;8:100–10.

    Google Scholar 

  34. Williams SD, Stablein DM, Einhorn LE, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testis cancer.N Engl J Med 1987;317:1433–8.

    PubMed  CAS  Google Scholar 

  35. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of primary retroperitoneal lymph node dissection.J Urol 1994;152:424–7.

    PubMed  CAS  Google Scholar 

  36. Skinner DG, Melamed A, Lieskovsky G. Complications of thoracoabdominal retroperitoneal lymph node dissection.J Urol 1982;127:1107–10.

    PubMed  CAS  Google Scholar 

  37. Jewett MAS, Wesley James T. Early and late complications of retroperitoneal lymphadenectomy in testis cancer.Can J Surg 1991;34:368–72.

    PubMed  CAS  Google Scholar 

  38. Sago AL, Ball TP, Novicki DE. Complications of retroperitoneal lymphadenectomy.Urology 1979;13:241–3.

    Article  PubMed  CAS  Google Scholar 

  39. Donohue JP. Complications of lymph node dissections. In: Marshall F, ed.Urological complications. St. Louis, MO: Mosby Year Book, 1990:384–401.

    Google Scholar 

  40. Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH. Cisplatin-based combination chemotherapy for disseminated germ cell tumors long term follow up.J Clin Oncol 1988;6:1239–47.

    PubMed  CAS  Google Scholar 

  41. Boyer M, Raghavan D. Toxicity of germ cell tumors.Semin Oncol 1992;19:128–42.

    PubMed  CAS  Google Scholar 

  42. Moul JW, Robertson JE, George SL, Paulson D, Walther P. Complications of therapy for testicular cancer.J Urol 1989;142:1491–6.

    PubMed  CAS  Google Scholar 

  43. Stoter G, Koopman A, Vendrick CPJ, et al. Ten year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine and bleomycin.J Clin Oncol 1989;7:1099–104.

    PubMed  CAS  Google Scholar 

  44. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC. A randomized trial of standard chemotherapy versus a high dose regimen in the treatment of poor prognosis non-seminomatous germ cell tumors.J Clin Oncol 1988;6:1031–40.

    PubMed  CAS  Google Scholar 

  45. Levi JA, Thomson D, Sandeman T, et al. A prospective study of cisplatin based combination chemotherapy in advanced germ cell malignancy role of maintenance and long term follow up.J Clin Oncol 1988;6:1154–60.

    PubMed  CAS  Google Scholar 

  46. Bosl GJ, Lange PH, Fraley EE, et al. Vinblastine, bleomycin and cisdiamminedichloroplatinum in the treatment of advanced testicular carcinoma. Possible importance of longer induction and shorter maintenance schedules.Am J Med 1980;68:492–6.

    Article  PubMed  CAS  Google Scholar 

  47. Vugrin D, Cvitkovic E, Whitmore WF Jr, Chang E, Golbey RB. VAB-4 combination chemotherapy in the treatment of metastatic testis tumors.Cancer 1981;47:833–9.

    PubMed  CAS  Google Scholar 

  48. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.N Engl J Med 1987;316:1435–40.

    PubMed  CAS  Google Scholar 

  49. Baniel J, Foster RS, Donohue JP, Einhorn LH. Late relapse of testicular cancer [Abstract 70].J Urol 1994;151:245.

    Google Scholar 

  50. Terebelo HR, Taylor GH, Brown A, et al. Late relapse of testicular cancerJ Clin Oncol 1983;1:566–71.

    PubMed  CAS  Google Scholar 

  51. Deleo MJ, Greco FA, Hainsworth JD, Hainsworth JD, Johnson DH. Late recurrences in long term survivors of germ cell neoplasms.Cancer 1988;62:985–8.

    PubMed  CAS  Google Scholar 

  52. Geier LJ, Volk SA, Weldon T, Redmond J 3rd. Late relapse in testicular cancer after chemotherapy.Lancet 1983;1:1049.

    PubMed  CAS  Google Scholar 

  53. Fossa SD, Ous S, Abyholm T, Norman N, Loeb M. Post treatment fertility in patients with testicular cancer. II. Influence of cisplatin based combination chemotherapy and of retroperitoneal surgery on hormone and sperm cell production.Br J Urol 1985;57:210–4.

    PubMed  CAS  Google Scholar 

  54. Carrol PR, Morse MJ, Whitmore WF, et al. Fertility status of patients with clinical stage I testis tumors on a surveillance protocol.J Urol 1987;137:70–3.

    Google Scholar 

  55. Foster RS, McNulty A, Rubin LR, et al. The fertility of patients with clinical stage I testis cancer managed by nerve-sparing retroperitoneal lymph node dissection.J Urol 1994;152:1139–42.

    PubMed  CAS  Google Scholar 

  56. Aass N, Kaasa S, Lund E, Kaalhus O, Heier MS, Fossa SD. Long term somatic side effects and morbidity in testicular cancer patients.Br J Cancer 1990;61:151–5.

    PubMed  CAS  Google Scholar 

  57. Drasga RE, Einhorn LH, Williams SD, Patel DW, Stevens EE. Fertility after chemotherapy for testicular cancer.J Clin Oncol 1983;1:179–83.

    PubMed  CAS  Google Scholar 

  58. Horwich A, Norman A, Fisher C, Hendry WF, Nicholls HJ, Dearnaley DP. Primary chemotherapy for stage II nonseminomatous tumors of the testis.J Urol 1994;151:72–8.

    PubMed  CAS  Google Scholar 

  59. Berthelsen JG. Testicular cancer and fertility.Int J Androl 1987;10:371–3.

    PubMed  CAS  Google Scholar 

  60. Shover LR, vonEschenbach AC. Sexual and marital counseling with men treated for testicular cancer.J Sex Marital Ther 1984;10:29–40.

    Google Scholar 

  61. Moynihan C. Testicular cancer: the psychosocial problems of patients and their relatives.Cancer Surv 1987;6:477–510.

    PubMed  CAS  Google Scholar 

  62. Fossa S, Aass N, Kaalhus O. Testicular cancer in young norwegians.J Surg Oncol 1988;39:43–63.

    PubMed  CAS  Google Scholar 

  63. Malec JF, Ronsaas MS, Trump DL. Psychological and personality disturbance among patients with testicular cancer.J Psychosoc Oncol 1985;3:55–64.

    Google Scholar 

  64. Aass N, Grunfeld B, Kaalhus O, Fossa SD. Pre-and post-treatment sexual life in testicular cancer patients: a descriptive investigation.B J Cancer 1993;67:1113–7.

    CAS  Google Scholar 

  65. Young BJ, Bultz BD, Russell JA, Trew MS. Compliance with follow-up of patients treated for non-seminomatous testicular cancer.Br J Cancer 1991;64:606–8.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Department of Urology, Indiana University Medical Center, Indianapolis, Indiana, USA

    Jack Baniel MD,  Richard S. Foster MD & John P. Donohue MD

  2. Division of Hematology and Oncology, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA

    Bruce J. Roth MD

Authors
  1. Jack Baniel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce J. Roth MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard S. Foster MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John P. Donohue MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baniel, J., Roth, B.J., Foster, R.S. et al. Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors. Annals of Surgical Oncology 3, 86–93 (1996). https://doi.org/10.1007/BF02409057

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02409057

Key Words

Search

Navigation